A potential explanation for this discrepancy is different expression levels and epigenetic modifications controlling the expression of cereblon, Ikaros, and Aiolos, between cancer cell lines and primary cells, as well as differing downstream IL-2-mediated effects following pomalidomide treatment (59). The gene discussed is IL2; the disease is cancer.